The city’s Economic Development Committee, which was set to vote on the downtown project’s $98 million bond financing package on Tuesday, chose to wait until February after making a few changes.
The local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent on the process for making the active ingredient.
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly’s Icos subsidiary.
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
Alecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit, will leave to become president of Mills College in Oakland, Calif. DeCoudreaux, 55, has worked at Indianapolis-based Lilly for 30 years after earning her law degree from Indiana University in Bloomington. As general counsel for its U.S. business, DeCoudreaux guided Lilly through all U.S. regulations, including its applications with the Food and Drug Administration to launch new drugs.
Carmel-based Zotec Partners has hired Bradley Myers as director of marketing. Prior to joining Zotec, Myers was the marketing specialist for Medical Management Professionals Inc. Myers has a marketing degree from George Mason University.
John H. Johnson, president of Indianapolis-based Eli Lilly and Co.’s oncology unit, will resign on Friday to become CEO of East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc. Johnson had been CEO of New York-based ImClone Systems Inc. when Lilly acquired it in 2008.
Eli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease, but so far analysts are unimpressed.
Plenty of opportunities await city officials bent on making downtown shine for the massive event.
The Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year ago. Profit per share beat Wall Street forecasts by a penny.
Eli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
The West Lafayette company does not yet market a product and has not yet reported a profit.
The private club’s president alerted members to the theft in a letter, but declined to specify how much was taken. Still, he said the director, who is not named in the correspondence, is making restitution.
Indianapolis manufacturer lines up deals with the Navy and Air Force worth a total of $225 million.
After a federal judge in Florida struck down the entire health reform law, investors shrugged. But the uncertainty for executives in health care companies increased.
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
Eli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung cancer drug over concerns about patients developing blood clots.
John Merriweather went from the Army at 18—he earned a Commendation Medal in Desert Storm—to a small company in Carmel where he learned all facets of the business, from warehousing to quality control to sales. Now 38, he runs his own firm.
We understand the concern expressed by some on the City-County Council over Indianapolis’ role in financing the $155 million project, but there are compelling reasons to approve it.
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
Interest rates on municipal bonds have ticked up in the last two months to pre-recession levels as investors have pulled their money from bond funds in droves. That pattern has begun, gradually, to reverse, but the higher rates could add to the cost of issuing debt for pending city projects.
